the funniest thing about this pathetic valuation is that back when their cholesterol drug was going through preclinical studies market cap was a 70 million market cap even before GLP was passed on a potential market of 900 million dollars, which NYR was on par to FDA approved drugs as shown below:
Forward to now which NYR is showing potential to being superior to any other drug out there for a 4 billion dollar market. 20 million market cap absolutely laughable. Anyways I’m off for the weekend had my rant and the company has a ton of news flow coming up which only make the company stronger. Cheers mate have a good weekend
Ann: NYR Completes Safety Studies Ahead of Phase I Clinical Trial, page-26
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $63.43M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 29.0¢ | $245.6K | 829.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 29101 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 311729 | 2 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| NYR (ASX) Chart |